*Financial Support*: This work was supported by the Swedish Brain Foundation, Swedish Research Council, Swedish Headache Society, and Karolinska Institutet.

*Conflict of Interest*: None.

CH

:   cluster headache

HCRTR2

:   hypocretin receptor 2

HWE

:   Hardy‐Weinberg equilibrium

SNP

:   single nucleotide polymorphism

Introduction {#head13462-sec-0006}
============

Cluster headache (CH) is a severe neurovascular disorder characterized by recurring attacks of unilateral, excruciating pain, but the pathophysiology is not yet fully understood. The activation of the trigeminal system leading to vasodilatation may be the source of pain and autonomic symptoms, but is not specific to CH.[1](#head13462-bib-0001){ref-type="ref"} As opposed to other primary headache disorders, such as migraine or tension‐type headache, CH shows a distinct circadian and circannual regularity of the attacks in a majority of patients, strongly suggesting involvement of the biological clock, which is regulated in the hypothalamic region of the brain.[2](#head13462-bib-0002){ref-type="ref"}, [3](#head13462-bib-0003){ref-type="ref"}, [4](#head13462-bib-0004){ref-type="ref"} Moreover, it has been determined that the hypothalamus is active during an attack,[5](#head13462-bib-0005){ref-type="ref"} and the secretion of hormones exhibiting a circadian rhythm, such as melatonin and cortisol, is irregular in CH patients.[6](#head13462-bib-0006){ref-type="ref"}, [7](#head13462-bib-0007){ref-type="ref"} For this reason, the hypothalamus has been a main focus of investigations on the pathophysiology of CH.

The neuropeptides hypocretin 1 and 2 (orexin A and B) are selectively synthesized in the lateral and posterior hypothalamus, and serve as ligands for the G protein‐coupled hypocretin (orexin) receptors 1 and 2 (HCRTR1 and HCRTR2).[8](#head13462-bib-0008){ref-type="ref"} These neuropeptides regulate neuroendocrine and autonomic functions, such as arousal, wakefulness, and appetite, via the activation of HCRTR1 and HCRTR2.[9](#head13462-bib-0009){ref-type="ref"}, [10](#head13462-bib-0010){ref-type="ref"} Interestingly, Bartsch et al have demonstrated that HCRTR1/2 activation in the posterior hypothalamus affects the modulation of nociceptive input and might therefore provide a link to head pain and autonomic symptoms commonly seen in primary headaches.[11](#head13462-bib-0011){ref-type="ref"} The *HCRTR2* gene has been investigated in more detail, and some studies have shown an association of *HCRTR2* with disorders like canine narcolepsy,[12](#head13462-bib-0012){ref-type="ref"} Alzheimer's disease,[13](#head13462-bib-0013){ref-type="ref"} as well as CH.[14](#head13462-bib-0014){ref-type="ref"}, [15](#head13462-bib-0015){ref-type="ref"}, [16](#head13462-bib-0016){ref-type="ref"}

Previous studies have demonstrated a genetic contribution to CH, and 7‒20% of the patients report a first‐, second‐, or third‐degree relative who has also been diagnosed with CH.[17](#head13462-bib-0017){ref-type="ref"}, [18](#head13462-bib-0018){ref-type="ref"} The identification of human sequence polymorphisms that affect genes, mRNA and/or proteins is key to understanding complex genetic diseases. Several candidate genes for CH have been investigated, for example *ADH4*,[19](#head13462-bib-0019){ref-type="ref"}, [20](#head13462-bib-0020){ref-type="ref"}, [21](#head13462-bib-0021){ref-type="ref"} *NOS*,[22](#head13462-bib-0022){ref-type="ref"} *CACNA1A*,[23](#head13462-bib-0023){ref-type="ref"} *MTHFR*,[24](#head13462-bib-0024){ref-type="ref"} and the 2 clock genes, *PER3* [25](#head13462-bib-0025){ref-type="ref"} and *CLOCK*.[26](#head13462-bib-0026){ref-type="ref"}, [27](#head13462-bib-0027){ref-type="ref"}, [28](#head13462-bib-0028){ref-type="ref"} In this study, we analyzed 3 genetic variants in the gene *HCRTR2* that have previously been screened and reported to associate with CH in different CH cohorts in Europe. The single nucleotide polymorphism (SNP) rs2653349 in exon 5 of *HCRTR2*, is a non‐synonymous variant that leads to an amino acid change from isoleucine to valine in the corresponding protein, which is speculated to have an influence on the dimerization process of the receptor.[16](#head13462-bib-0016){ref-type="ref"} This SNP has been screened and tested for association with CH with conflicting results,[14](#head13462-bib-0014){ref-type="ref"}, [15](#head13462-bib-0015){ref-type="ref"}, [20](#head13462-bib-0020){ref-type="ref"}, [29](#head13462-bib-0029){ref-type="ref"}, [30](#head13462-bib-0030){ref-type="ref"} whereas the intronic *HCRTR2* SNPs rs3122156 (intron 1) and rs2653342 (intron 4) were linked to the disease in a haplotype analysis by Rainero et al.[16](#head13462-bib-0016){ref-type="ref"}

Materials and Methods {#head13462-sec-0007}
=====================

Study Population and Material {#head13462-sec-0008}
-----------------------------

The study material consists of 517 CH patients and 581 controls (Table [1](#head13462-tbl-0001){ref-type="table"}) and was obtained after approval by the local ethics committee in Stockholm and informed consent of the research subjects. CH patients (mean age: 52.4 years; 68.3% men) were recruited at the Karolinska University Hospital; 439 of these patients have completed a questionnaire regarding clinical data, medication, and lifestyle. Patients were diagnosed with CH according to the International Classification of Headache Disorders (ICHD‐III) criteria.[31](#head13462-bib-0031){ref-type="ref"} Control subjects were 570 anonymous blood donors with unknown age (54.9% men), as well as 11 neurologically healthy individuals not diagnosed with CH (mean age: 43.5 years; 54.5% men) recruited at Karolinska University Hospital, representing a general Swedish population (<https://geblod.nu/english-engelska/>). DNA was purified from whole blood samples using the Gentra Puregene Blood Kit (QIAGEN, Hilden, Germany) according to manufacturer's instructions.

###### 

Demographic Characterization

                                                                        CH Patients   Controls
  --------------------------------------------------------------------- ------------- ------------
  Number of individuals                                                 517           581
  Age (years)                                                           52.4          n/a
  Age at onset (years)                                                  32.4          --
  Male % (n)                                                            68.3 (353)    54.9 (319)
  Heredity[^†^](#head13462-note-0002){ref-type="fn"} % (n)              12.5 (59)     n/a
  Episodic CH % (n)                                                     89.6 (463)    --
  Diurnal rhythmicity[^†^](#head13462-note-0002){ref-type="fn"} % (n)   68.3 (300)    --

Based on a subgroup of patients for whom detailed information was available: 472 individuals (heredity) and 439 individuals (diurnal rhythmicity). CH, cluster headache; n/a, not available.
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Genotyping by Quantitative Real‐Time PCR (qPCR) {#head13462-sec-0009}
-----------------------------------------------

The DNA samples were genotyped using predesigned TaqMan® SNP Genotyping assays on an ABI 7500 FAST Real‐Time PCR instrument (Applied Biosystems, Foster City, CA, USA). The following assays were used: C_429384_20 (rs2653342), C_1507491_10 (rs2653349), C_26549175_10 (rs3122156). Genotyping was run with the predesigned TaqMan® primer and probe (1:80), TaqMan® genotyping master mix (1:2), and 2--5 ng DNA in a total reaction volume of 10 µL using the recommended qPCR conditions for the SNP assays, except for the cycling procedure: 15 seconds at 92ºC and 90 seconds at 60ºC for 55 cycles. A post‐PCR read was performed for allelic discrimination using the 7500 software version 2.0.4 (Applied Biosystems) supplied with the instrument.

Genotyping by Pyrosequencing {#head13462-sec-0010}
----------------------------

For the *HCRTR2* polymorphism rs2653342, randomly selected samples were additionally genotyped by pyrosequencing to confirm the TaqMan® assay results, where the distinction between the 3 genotype clusters was consistently poor. Primers (forward: 5′‐CTCGCTGTCATCTTT GTATCCC‐3′; reverse: 5′‐TCGGAGTAACTGGGCAATAGA‐3′) for the preceding PCR and the pyrosequencing primer (5′‐CCTATAAATAGCAC‐3′) were designed using the web‐based softwares Primer3[32](#head13462-bib-0032){ref-type="ref"} and mfold.[33](#head13462-bib-0033){ref-type="ref"} Primer sequences were screened on the NCBI webpage (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to confirm specificity. The PCR was carried out using a non‐biotinylated forward and a biotinylated reverse primer as well as Taq polymerase (Thermo Scientific, Ulm, Germany) to amplify fragments. The biotinylated PCR products were immobilized onto streptavidin‐coated sepharose beads (GE Healthcare, Uppsala, Sweden) using a PyroMark® vacuum prep tool (QIAGEN), denatured and purified in 70% ethanol, 0.2 M NaOH, and washing buffer according to manufacturer's instructions, and finally annealed to the sequencing primer for 2 minutes at 80ºC. The SNP was analyzed using a PyroMark® Reagent Kit and Q96 ID system (QIAGEN). Samples rerun with pyrosequencing corresponded 100% with the TaqMan® assay results for the 3 different genotypes, and the original TaqMan® results were therefore considered reliable.

Statistical Analysis {#head13462-sec-0011}
--------------------

Power calculations were made with the free power and sample size calculation software PS v3.0.[34](#head13462-bib-0034){ref-type="ref"} With this sample size (n = 1098) and an estimated minor allele frequency of 0.15 in individuals with European descent (<http://www.ncbi.nlm.nih.gov/SNP>), we have 80% power to detect true odds ratios for CH below 0.59 or above 1.55, respectively. Deviation from the Hardy‐Weinberg equilibrium (HWE) was tested for using the web‐based Online Encyclopedia for Genetic Epidemiology studies software.[35](#head13462-bib-0035){ref-type="ref"} Genotype association was evaluated with chi‐square (χ^2^) test and allele association was analyzed with Fisher's exact test or χ^2^ test (for N \> 2000) using GraphPad Prism v5.04 (GraphPad Software Inc, La Jolla, CA, USA). Both tests were run with Bonferroni correction for multiple testing when applicable. For logistic regression analysis with sex as covariate, PLINK whole genome association analysis toolset v1.07[36](#head13462-bib-0036){ref-type="ref"} was used. Haplotype analysis and permutation test with 10,000 permutations were performed in Haploview v4.2.[37](#head13462-bib-0037){ref-type="ref"}

In Silico Analysis {#head13462-sec-0012}
------------------

To evaluate the possible effect of the non‐synonymous SNP rs2653349 on the mRNA structure of *HCRTR2*, the secondary structure was predicted using the publicly available software mfold.[33](#head13462-bib-0033){ref-type="ref"} Partial *HCRTR2* mRNA sequences, including flanking sequences (70 nucleotides) on each side of the SNP, were analyzed and compared to the wild‐type sequence.

Results {#head13462-sec-0013}
=======

We analyzed 3 SNPs in *HCRTR2* (rs3122156, rs2653342, and rs2653349), as shown in Table [2](#head13462-tbl-0002){ref-type="table"}. For each SNP we found all 3 genotypes present in both CH patients and controls. The observed frequencies of patients and controls were in agreement with the HWE for rs2653342 and rs2653349 (data not shown). For rs3122156, only patients were in agreement with HWE (χ^2^ * *=* *0.27, *P *=* *.60), and in the controls we detected an excess of homozygotes (data not shown). Further genetic analysis showed there was a significant difference in occurrence of the less common allele (G) between CH patients and controls (*P *=* *.0421) for rs3122156 (Table [2](#head13462-tbl-0002){ref-type="table"}). The G allele was more prevalent in controls (29.9%) than in patients (25.9%), indicating that rs3122156 might constitute a protective factor for CH. However, this significance did not remain after correction for multiple testing. No association with CH was found in genotype or allele frequencies for rs2653342 and rs2653349. Additionally, logistic regression analysis was performed with sex as covariate, in order to exclude any bias introduced by the skewed sex ratio in the patient group (68.3% males in the patient group vs 54.9% males in the control group). The analysis was run under a full genotypic as well as dominant or additive model. Under the dominant and the full genotypic model no association between any of the 3 SNPs and CH was found (data not shown). Using the additive model, there was a significant association with CH for rs3122156, even after correction for multiple testing (*P~corr~ *=* *0.0492). In summary, using 2 different statistical methods, we could determine that there is no significant difference on the genotypic level, but a weak association with CH on the allelic level.

###### 

Genotype and Allele Frequencies for 3 *HCRTR2* SNPs in Controls (n = 581) and CH Patients (n = 517)

                                        Controls % (n)   CH Patients % (n)   χ^2^ (df)           OR (95% CI)   *P* Value   *P* ~corr~ Value
  ----------- ------------ ------------ ---------------- ------------------- ------------------- ------------- ----------- ------------------
  rs3122156   Genotype     TT           51.4 (298)       55.3 (286)          5.620 (2)                         .0602       
  TG          37.4 (217)   37.5 (194)                                                                                      
  GG          11.2 (65)    7.2 (37)                                                                                        
  Allele      T            70.1 (813)   74.1 (766)       4.129 (1)           0.82 (0.68--0.99)   .0421         .1263       
  G           29.9 (347)   25.9 (268)                                                                                      
  rs2653342   Genotype     GG           73.2 (424)       72.1 (373)          1.951 (2)                         .3770       
  GA          24.2 (140)   26.3 (136)                                                                                      
  AA          2.6 (15)     1.5 (8)                                                                                         
  Allele      G            85.3 (988)   85.3 (882)       0.002 (1)           1.00 (0.79--1.27)   .9622                     
  A           14.7 (170)   14.7 (152)                                                                                      
  rs2653349   Genotype     GG           66.3 (385)       64.2 (332)          0.854 (2)                         .6525       
  GA          29.9 (174)   32.5 (168)                                                                                      
  AA          3.8 (22)     3.3 (17)                                                                                        
  Allele      G            81.2 (944)   80.5 (832)       0.165 (1)           1.05 (0.85--1.30)   .6843                     
  A           18.8 (218)   19.5 (202)                                                                                      

χ^2^, chi‐square; CH, cluster headache; CI, confidence interval; df, degrees of freedom; OR, odds ratio; *P* ~corr~ value, *P* value corrected for multiple testing.
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Since about 68% of the patients who filled out the questionnaire reported that they experience a temporal pattern in attack recurrence, a stratified analysis was performed. In this additional analysis, the genotype and allele frequencies from CH patients with diurnal rhythmicity were compared to controls for the 3 SNPs in *HCRTR2.* The stratified analysis did not yield a significant association of CH with any of the 3 *HCRTR2* SNPs (data not shown).

A haplotype analysis was carried out for the 3 *HCRTR2* polymorphisms, and only subjects with a known genotype for all SNPs (n = 1095) were included (Table [3](#head13462-tbl-0003){ref-type="table"}). The position of each SNP in the *HCRTR2* haplotypes is as follows: (1) rs3122156, (2) rs2653342, and (3) rs2653349. The haplotype G‐G‐G with the minor allele for rs3122156 and the major alleles for rs2653342 and rs2653349 had a higher frequency in control subjects than CH patients, which suggests that this haplotype is a protective factor (*P *=* *.0264). However, the significance was lost when performing a permutation test (*P~permut~ *=* *.1160).

###### 

Haplotype Analysis for 3 *HCRTR2* SNPs in CH Patients and Controls

  Haplotype                                         Control   CH Patients   χ^2^ (df* *=* *2)   *P*Value   *P~permut~* Value           
  ------------------------------------------------- --------- ------------- ------------------- ---------- ------------------- ------- -------
  T‐G‐G[^†^](#head13462-note-0005){ref-type="fn"}   640       55.4          606                 58.6       2.367               .1239   
  G‐G‐G                                             297       25.7          224                 21.6       4.932               .0264   .1160
  T‐A‐A                                             158       13.7          148                 14.3       0.161               .6881   
  G‐G‐A                                             41        3.5           42                  4.1        0.482               .4873   
  T‐G‐A                                             9         0.8           10                  0.9        0.116               .7334   
  G‐A‐A                                             8         0.6           2                   0.2        2.545               .1107   
  T‐A‐G                                             3         0.3           2                   0.2        0.101               .7506   

χ^2^, chi‐square; CH, cluster headache; df, degrees of freedom;*P~permut~* value, *P* value after test with 10,000 permutations.

Reference haplotype (T‐G‐G) corresponds to wild‐type allele of each *HCRTR2* single nucleotide polymorphism (SNP) where rs3122156 is in position 1, rs2653342 in position 2, and rs2653349 in position 3.

John Wiley & Sons, Ltd

Our in silico analysis of mRNA folding shows that rs2653349 leads to changes in secondary structure and mRNA folding energy (ΔG), 34.34 kcal/mol (A allele) vs 36.70 kcal/mol (G allele) (Fig. [1](#head13462-fig-0001){ref-type="fig"}).

![Comparison of mRNA folding with the 2 different rs2653349 alleles. Structures were generated using the mfold program. (A) The mRNA structure with the A allele has an initial folding energy of ΔG* *= −34.34 kcal/mol. (B) The mRNA structure with the G allele has a mean folding energy of ΔG* *= −36.70 kcal/mol. The G allele leads to a small additional loop in the mRNA structure.](HEAD-59-410-g001){#head13462-fig-0001}

Discussion {#head13462-sec-0014}
==========

Genotypic and allelic analysis of the investigated *HCRTR2* polymorphisms in CH patients suggests that there is no association between rs2653342 or rs2653349 and CH in Sweden. However, a trend for a protective effect of the rs3122156 minor allele G on the *HCRTR2* gene could be seen, which is in agreement with an earlier work by Rainero et al.[16](#head13462-bib-0016){ref-type="ref"} Moreover, haplotype analysis of the 3 *HCRTR2* polymorphisms revealed a significantly associated protective haplotype, which included the minor allele for rs3122156 and the major alleles for rs2653342 and rs2653349. However, this association is most likely due to presence of the rs3122156 minor allele. Interestingly, the observed frequencies of controls, but not patients, deviated from the HWE for rs3122156. This could possibly be explained by that the locus is under selection, which leads to a false observation of excess homozygotes. When comparing genotype and allele frequencies of patients and controls with data from the 1000 Genomes Project (<http://www.ensembl.org/Homo_sapiens/Info/Index>) and previous reports for this SNP, it becomes obvious that our control population, as well as controls from Italy (Rainero et al), has a higher frequency for the less frequent homozygous genotype GG (11.2% and 12.8% vs 7.4%) and the G allele (29.9% and 32.0% vs 27.6%) compared to 1000 Genomes (Table [4](#head13462-tbl-0004){ref-type="table"}).[16](#head13462-bib-0016){ref-type="ref"} This might be caused by a positive selection for this SNP in these 2 control populations, but could also depend on genotyping errors or the existence of population stratification. Taken together, these results suggest a protective role for the less common G allele of rs3122156 on the *HCRTR2* gene in CH in the Swedish population. Additionally, an in silico analysis of mRNA folding shows that rs2653349 can lead to minor changes in the mRNA structure, which could affect, for example, mRNA stability of *HCRTR2*.

Rainero et al[16](#head13462-bib-0016){ref-type="ref"} performed a haplotype analysis of 6 *HCRTR2* polymorphisms including the 3 SNPs analyzed in this project. They found a haplotype associated with CH that contains the wild‐type alleles for rs3122156 and rs2653349, and the mutant allele for rs2653342. This allele combination was only found at very low frequencies in our material with no difference between cases and controls. The finding of this significant risk haplotype might be influenced by the strong association found for rs2653349 in Rainero's cohort. Interestingly, all haplotypes in Rainero's study containing the allele combination from the protective haplotype G‐G‐G in our study were slightly more common in controls than cases, although not significantly. However, despite the differences in haplotype frequencies and results, this points to a role of the haplotype G‐G‐G in protecting from developing CH across different populations.

An association of rs2653349 with CH was reported in an Italian[14](#head13462-bib-0014){ref-type="ref"} and a German[15](#head13462-bib-0015){ref-type="ref"} cohort, but could not be confirmed in a second Italian cohort,[20](#head13462-bib-0020){ref-type="ref"} a Chinese Han cohort,[28](#head13462-bib-0028){ref-type="ref"} a mixed Northern European (British, Danish, and Swedish) cohort,[29](#head13462-bib-0029){ref-type="ref"} and a Dutch cohort (Table [4](#head13462-tbl-0004){ref-type="table"}).[30](#head13462-bib-0030){ref-type="ref"} The genotype and allele frequencies at rs2653349 observed in our material correspond to those reported for controls in previous studies from Germany, the Netherlands, and in the British and Swedish cohorts from the study by Baumber et al. However, they differ substantially from the 2 Italian studies and Baumber's Danish cohort. Since our Swedish cohort, with the second largest sample size after the Dutch study, did not show an association with CH, this study adds to the conflicting results of previous ones and no definite conclusion can be drawn regarding rs2653349 and CH. The differences observed in genotype and allele frequencies of the control groups hint that the effect might be population‐dependent.

###### 

Comparison of Minor Allele Frequencies of rs3122156, rs2653342, and rs265334

  Study                                                                                               Minor Allele Frequency                                                           
  --------------------------------------------------------------------------------------------------- ------------------------ ------------- ------------- ------------- ------------- -------------
  Fourier et al                                                                                       0.259 (268)              0.299 (347)   0.147 (152)   0.147 (170)   0.195 (202)   0.188 (218)
  1000 Genomes (EUR)                                                                                  --                       0.276 (278)   --            0.147 (148)   --            0.184 (185)
  Rainero et al[14](#head13462-bib-0014){ref-type="ref"}, [16](#head13462-bib-0016){ref-type="ref"}   0.216 (47)               0.320 (135)   0.257 (56)    0.166 (70)    0.037 (8)     0.126 (53)
  Zarilli et al[20](#head13462-bib-0020){ref-type="ref"}                                              --                       --            --            --            0.120 (13)    0.078 (31)
  Schürks et al[15](#head13462-bib-0015){ref-type="ref"}                                              --                       --            --            --            0.133 (60)    0.201 (107)
  Baumber et al[29](#head13462-bib-0029){ref-type="ref"} (British)                                    --                       --            --            --            0.190 (24)    0.208 (37)
  Baumber et al[29](#head13462-bib-0029){ref-type="ref"} (Swedish)                                    --                       --            --            --            0.173 (34)    0.220 (46)
  Baumber et al[29](#head13462-bib-0029){ref-type="ref"} (Danish)                                     --                       --            --            --            0.219 (42)    0.271 (39)
  Weller et al[30](#head13462-bib-0030){ref-type="ref"}                                               --                       --            --            --            0.210 (242)   0.227 (397)
  Fan et al[28](#head13462-bib-0028){ref-type="ref"}                                                  0.290 (65)               0.255 (98)    0.058 (13)    0.044 (17)    0.067 (15)    0.042 (16)

CH, cluster headache.
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One possible limitation of our study is the lack of clinical information for our control material since we cannot exclude the occurrence of CH patients in the control group. However, statistically the occurrence of CH should be extremely low, or non‐existent, corresponding to the prevalence of CH in the Swedish population (0.05‐0.1).[38](#head13462-bib-0038){ref-type="ref"}

Conclusion {#head13462-sec-0015}
==========

To conclude, in our Swedish cohort we found a trend of association between the protective variant rs3122156 in *HCRTR2* and CH. We could not confirm the association between the 2 *HCRTR2* SNPs rs2653342 and rs2653349 conferring increased risk for CH as was suggested in previous studies performed by other groups.
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